Cargando…

Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia

BACKGROUND: Umbilical cord blood transplantation (UCBT) from unrelated donors is one of the successful treatments for acute leukemia in childhood. The most frequent side effect of UCBT is peri-engraftment syndrome (PES), which is directly associated with the greater prevalence of acute and chronic g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xin-Yu, Zhan, Li-Ping, Liu, Dian-Dian, Han, Xia-Wei, Chen, Han, Wu, Zheng-Zhou, Wang, Yin, Que, Li-Ping, Wu, Xiao-Jun, Liu, Su, Wang, Kai-Mei, Huang, Shao-Liang, Fang, Jian-Pei, Huang, Ke, Xu, Hong-Gui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675180/ https://www.ncbi.nlm.nih.gov/pubmed/36401208 http://dx.doi.org/10.1186/s12885-022-10309-9

Ejemplares similares

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA
por: Zu, Yingling, et al.
Publicado: (2021)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

Unrelated umbilical cord blood transplantation for children with hereditary leukodystrophy: A retrospective study
por: Wang, Ping, et al.
Publicado: (2022)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

Unrelated umbilical cord blood can improve the prognosis of haploidentical hematopoietic stem cell transplantation
por: Yang, Ying, et al.
Publicado: (2022)

Umbilical cord blood: A promising source for allogeneic CAR-T cells
por: Liu, Dian-Dian, et al.
Publicado: (2022)

Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia
por: Gomyo, Ayumi, et al.
Publicado: (2020)

Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2021)

Human Umbilical Cord Mesenchymal Stem Cells Therapy in Cyclophosphamide-Induced Premature Ovarian Failure Rat Model
por: Song, Dan, et al.
Publicado: (2016)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study
por: Yang, Jun, et al.
Publicado: (2018)

Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors
por: Montoro, Juan, et al.
Publicado: (2016)

Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
por: Patel, Dilan A., et al.
Publicado: (2020)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood
por: Xu, Xiaoqian, et al.
Publicado: (2020)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractory Cytomegalovirus Retinitis after Unrelated Umbilical Cord Blood Transplantation
por: Li, Na, et al.
Publicado: (2022)

Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation
por: Sun, Xi, et al.
Publicado: (2021)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Efflux capacity and aldehyde dehydrogenase both contribute to CD8(+) T-cell resistance to posttransplant cyclophosphamide
por: Patterson, Michael T., et al.
Publicado: (2022)

Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
por: Patterson, Michael T., et al.
Publicado: (2023)

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
por: Liu, Wei-Hsin, et al.
Publicado: (2015)

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation
por: Wada, Fumiya, et al.
Publicado: (2023)

Comparison of two methods used for monitoring low-copy cytomegalovirus infection in a patient with chronic myeloid leukemia after unrelated umbilical cord blood transplantation
por: Dzieciątkowski, Tomasz, et al.
Publicado: (2007)

PB1752: ANALYSIS OF HLA-PEPTIDE BINDING POCKETS IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
por: Boukouaci, W., et al.
Publicado: (2022)

Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis
por: Liu, Yanying, et al.
Publicado: (2010)

Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide
por: Sumii, Yuichi, et al.
Publicado: (2023)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Single nucleotide polymorphisms within HLA region are associated with the outcomes of unrelated cord blood transplantation
por: Chen, Ding-Ping, et al.
Publicado: (2021)

Malakoplakia Affecting the Umbilical Cord
por: Han, Song-Hee, et al.
Publicado: (2015)

Umbilical Cord-Derived Mesenchymal Stem Cells for Hematopoietic Stem Cell Transplantation
por: Chao, Yu-Hua, et al.
Publicado: (2012)

Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2022)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
por: Benadiba, Joy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lnoicl747g4qhlrj0890dol6vm